



(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 37/06* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/IB2022/000443

(22) International Filing Date:
02 August 2022 (02.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/203,856 02 August 2021 (02.08.2021) US

(71) Applicant: **ARGENX BV** [BE/BE]; Industriepark Zwijnaarde 7, 9052 Ghent (BE).

(72) Inventors: **VAN BRAGT, Antoinetta Jacoba Maria**; c/o Argenx BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE). **ULRICHTS, Peter**; c/o Argenx BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE). **HOFMAN, Erik**; c/o Argenx BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE). **VERHEESEN, Peter**; c/o Argenx BV, Industriepark Zwijnaarde 7, 9052 Ghent (BE).


(74) Agent: **BOULT WADE TENNANT LLP** (ASSOC. NO. 505); Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SUBCUTANEOUS UNIT DOSAGE FORMS

FIGURE 1



(57) Abstract: Provided herein are unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*